DJS is developing novel therapeutics to treat chronic inflammatory diseases. Their lead programme is looking to revolutionise the treatment of high mortality fibrotic diseases, such as Idiopathic Pulmonary Fibrosis (IPF). They have produced the first ever antibody, DJS-002 which targets the disease.
